Defining a minimal clinically relevant difference for the unified Parkinson's rating scale: an important but still unmet need.
- 3 May 2006
- journal article
- editorial
- Published by Wiley in Movement Disorders
- Vol. 21 (8), 1059-1061
- https://doi.org/10.1002/mds.20913
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Rivastigmine for Dementia Associated with Parkinson's DiseaseNew England Journal of Medicine, 2004
- Multicenter, Open-Label, Trial of Sarizotan in Parkinson Disease Patients With Levodopa-Induced Dyskinesias (the SPLENDID Study)Clinical Neuropharmacology, 2004
- Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET studyAnnals of Neurology, 2003
- The Unified Parkinson's Disease Rating Scale (UPDRS): Status and recommendationsMovement Disorders, 2003
- A Controlled Trial of Rasagiline in Early Parkinson DiseaseArchives of Neurology, 2002
- A Five-Year Study of the Incidence of Dyskinesia in Patients with Early Parkinson's Disease Who Were Treated with Ropinirole or LevodopaNew England Journal of Medicine, 2000
- Clozapine in drug-induced psychosis in Parkinson's diseaseThe Lancet, 1999
- Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6‐month interim report of a 3‐year studyMovement Disorders, 1998
- Ropinirole in the treatment of early Parkinson's disease: A 6‐month interim report of a 5‐year levodopa‐controlled studyMovement Disorders, 1998
- Effect of Deprenyl on the Progression of Disability in Early Parkinson's DiseaseNew England Journal of Medicine, 1989